查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108358

人類微生物組市場分析及預測（至2035年）：類型、產品、服務、技術、應用、部署模式、最終用戶、功能

Human Microbiome Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Deployment, End User, Functionality
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球人類微生物組市場預計將從2025年的13億美元成長到2035年的86億美元，CAGR為20.8%。推動人類微生物組市場成長的因素包括微生物健康研究的進步、對基於微生物組的療法的需求不斷成長以及精準醫療方法的日益普及。據美國國立衛生研究院（NIH）表示，人類微生物組包含數兆微生物，它們在免疫、代謝和整體健康中發揮著非常重要的作用。元基因組組定序、生物資訊學和基於微生物組的藥物研發技術的進步加速其在胃腸道疾病、腫瘤、自體免疫疾病和個人化醫療等領域的應用。

人類微生物組市場的「類型」細分包括益生菌、益生元、合益素、後生元和其他產品。其中，益生菌因其在改善腸道健康、增強免疫功能以及透過有益微生物輔助疾病管理方面的廣泛應用而佔據較大的市場佔有率。隨著對腸道微生物組在整體健康中作用的認知不斷加深，對益生菌療法和補充劑的需求也不斷成長。益生元也因其促進有益菌生長和維持微生物組平衡的作用而備受關注。同時，合益素和後生元因其在標靶醫療介入、代謝紊亂和個人化醫療方面的潛在應用，正逐漸成為先進的微生物組解決方案。

市場區隔
類型 益生菌、益生元、合益素、後生元、其他
產品 食品、營養補充品、特殊醫學用途食品、嬰兒配方奶粉、其他
服務 微生物組測序、資料分析、諮詢、其他
技術 下一代定序、聚合酵素鏈鎖反應、其他
用途 治療、診斷、個人化醫療、其他
部署模式 本地部署、雲端部署、其他
最終用戶 製藥公司、生技公司、研究機構、其他
功能 腸道環境、免疫系統支持、代謝功能、其他

人類微生物組市場的「應用」領域包括治療、診斷、個人化醫療和其他領域。治療領域是主要應用領域，這得益於基於微生物組的療法在胃腸道疾病、免疫相關疾病、代謝性疾病和慢性疾病治療方面的持續發展。診斷領域也呈現強勁成長，因為微生物組分析技術能夠實現疾病的早期檢測、生物標記的識別，並加深對微生物對健康影響的理解。個人化醫療迅速發展，微生物組分析技術的進步使得基於個別微生物組組成的個人化治療策略成為可能。微生物組資料與臨床資訊的整合進一步推動了全球精準醫療解決方案的發展。

區域概覽

到2025年，北美佔據全球人類微生物組市場最大的佔有率，這主要得益於其先進的生物技術產業、強大的藥物研發能力以及對基於微生物組的療法不斷成長的投資。該地區擁有眾多領先的微生物組公司、學術研究機構和合約研究組織（CRO），它們正積極開發微生物組診斷、生物治療產品和精準醫療解決方案。胃腸道疾病、代謝性疾病和免疫相關疾病的日益普遍加速對微生物組研究和治療開發的需求。此外，政府機構和創業投資的有利資助，以及生技公司和製藥公司之間不斷擴大的合作，將繼續鞏固北美在人類微生物組市場的主導地位。

在亞太地區，受醫療保健領域投資增加、生物技術研究拓展以及人們對微生物組在疾病預防和治療中作用的認知不斷提高的推動，人類微生物組市場預計將實現最高成長。中國、日本、韓國、印度和新加坡等國家正大力投資基因組學、微生物組定序和精準醫療計畫，以推動醫療保健創新。胃腸道疾病、肥胖症、糖尿病和其他慢性疾病負擔的加重進一步推動了對基於微生物組的診斷和治療的需求。此外，政府支持、製藥和生物技術產業的擴張以及研究機構與全球企業之間合作的加強，預計將在預測期內加速全部區域微生物組技術的應用。

主要趨勢和促進因素

以微生物組為基礎的療法和生物製藥產品（LBPs）的擴展

人類微生物組市場正呈現強勁的發展趨勢，即開發以微生物組為基礎的療法和生物醫學產品。製藥和生物技術公司正日益利用微生物組定序、總體基因體學和微生物工程等領域的進步，開發針對胃腸道疾病、代謝性疾病、癌症和神經系統疾病的標靶治療。人工智慧（AI）和多組體學技術進一步推動了有益微生物菌株和生物標記的識別，實現個人化治療。隨著監管機構對基於微生物組的產品接受度不斷提高，以及研究機構與產業界合作的加強，創新加速，微生物組療法已成為現代醫療保健的關鍵領域。

慢性病盛行率不斷上升以及對個人化醫療的日益關注

慢性胃腸道疾病、肥胖、糖尿病、自體免疫疾病和癌症的日益普遍是推動人類微生物組市場發展的主要因素。科學證據顯示腸道微生物組與免疫功能、新陳代謝和整體健康密切相關，這促使製藥公司和醫療保健機構加大對微生物組研究和個人化治療策略的投資。基於微生物組的藥物研發資金增加、臨床試驗規模擴大以及新一代定序技術的進步，進一步推動了市場成長。此外，消費者對腸道健康的日益關注以及對靶向微生物組診斷和治療需求的成長，也持續為市場創造巨大的成長機會。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 益生菌
    • 益生元
    • 合益素
    • 後生元
    • 其他
  • 市場規模及預測：依產品分類
    • 食物
    • 補充
    • 特殊醫學用途食品
    • 嬰兒配方奶粉
    • 其他
  • 市場規模及預測：依服務分類
    • 微生物組定序
    • 資料分析
    • 諮詢
    • 其他
  • 市場規模及預測：依技術分類
    • 下一代定序
    • 聚合酵素鏈鎖反應
    • 其他
  • 市場規模及預測：依應用領域分類
    • 治療
    • 診斷
    • 個人化醫療
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究機構
    • 其他
  • 市場規模及預測：依功能分類
    • 腸道環境
    • 免疫系統支持
    • 代謝功能
    • 其他
  • 市場規模及預測：依部署方式分類
    • 現場
    • 雲端
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Seres Therapeutics
  • Enterome Bioscience
  • Second Genome
  • Vedanta Biosciences
  • 4D Pharma
  • Rebiotix
  • Finch Therapeutics
  • Synlogic
  • BiomeSense
  • Microbiotica
  • Evelo Biosciences
  • Axial Biotherapeutics
  • Kaleido Biosciences
  • AOBiome
  • Metabiomics
  • Osel
  • MaaT Pharma
  • BiomX
  • Quorum Innovations
  • Eligo Bioscience

第9章 關於我們

簡介目錄
Product Code: GIS20254

The global Human Microbiome Market is projected to grow from $1.3 billion in 2025 to $8.6 billion by 2035, at a compound annual growth rate (CAGR) of 20.8%. The human microbiome market is driven by growing research into microbial health, rising demand for microbiome-based therapeutics, and increasing adoption of precision medicine approaches. According to the National Institutes of Health (NIH), the human microbiome consists of trillions of microorganisms that play important roles in immunity, metabolism, and overall health. Advancements in metagenomic sequencing, bioinformatics, and microbiome-based drug development are accelerating applications in gastrointestinal disorders, oncology, autoimmune diseases, and personalized healthcare.

The Type segment of the Human Microbiome Market includes probiotics, prebiotics, synbiotics, postbiotics, and others. Among these, probiotics hold a significant market share due to their widespread use in improving gut health, enhancing immune function, and supporting disease management through beneficial microorganisms. The growing understanding of the gut microbiomes role in overall health is increasing demand for probiotic-based therapies and supplements. Prebiotics are also gaining traction as they promote the growth of beneficial bacteria and support microbiome balance, while synbiotics and postbiotics are emerging as advanced microbiome solutions due to their potential applications in targeted health interventions, metabolic disorders, and personalized healthcare.

Market Segmentation
TypeProbiotics, Prebiotics, Synbiotics, Postbiotics, Others
ProductFoods, Supplements, Medical Foods, Infant Formula, Others
ServicesMicrobiome Sequencing, Data Analysis, Consulting, Others
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Others
ApplicationTherapeutics, Diagnostics, Personalized Medicine, Others
DeploymentOn-Premise, Cloud-Based, Others
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Others
FunctionalityGut Health, Immune System Support, Metabolic Health, Others

The Application segment of the Human Microbiome Market includes therapeutics, diagnostics, personalized medicine, and others. Therapeutics represent a major application area due to the increasing development of microbiome-based treatments for gastrointestinal disorders, immune-related diseases, metabolic conditions, and chronic illnesses. Diagnostics are witnessing strong growth as microbiome analysis technologies enable early disease detection, biomarker identification, and improved understanding of microbial influences on health. Personalized medicine is expanding rapidly with advancements in microbiome profiling, allowing customized treatment strategies based on individual microbial compositions. The integration of microbiome data with clinical information is further supporting the development of precision healthcare solutions globally.

Geographical Overview

North America accounted for the largest share of the global human microbiome market in 2025, driven by its advanced biotechnology industry, strong pharmaceutical research capabilities, and increasing investments in microbiome-based therapeutics. The region benefits from the presence of leading microbiome companies, academic research institutions, and contract research organizations actively developing microbiome diagnostics, live biotherapeutic products, and precision medicine solutions. Growing prevalence of gastrointestinal disorders, metabolic diseases, and immune-related conditions has accelerated demand for microbiome research and therapeutic development. Furthermore, favorable funding from government agencies and venture capital firms, along with increasing collaborations between biotechnology and pharmaceutical companies, continues to strengthen North America's leadership in the human microbiome market.

Asia Pacific is expected to witness the highest growth in the human microbiome market owing to rising healthcare investments, expanding biotechnology research, and increasing awareness of the role of the microbiome in disease prevention and treatment. Countries including China, Japan, South Korea, India, and Singapore are investing significantly in genomics, microbiome sequencing, and precision medicine initiatives to advance healthcare innovation. The growing burden of gastrointestinal disorders, obesity, diabetes, and other chronic diseases is further driving demand for microbiome-based diagnostics and therapeutics. In addition, supportive government initiatives, expanding pharmaceutical and biotechnology industries, and increasing collaborations between research institutions and global companies are expected to accelerate the adoption of microbiome technologies across the region during the forecast period.

Key Trends and Drivers

Expansion of Microbiome-Based Therapeutics and Live Biotherapeutic Products:

The Human Microbiome Market is witnessing a strong trend toward the development of microbiome-based therapeutics and live biotherapeutic products (LBPs). Pharmaceutical and biotechnology companies are increasingly leveraging advances in microbiome sequencing, metagenomics, and microbial engineering to develop targeted treatments for gastrointestinal disorders, metabolic diseases, cancer, and neurological conditions. Artificial intelligence and multi-omics technologies are further improving the identification of beneficial microbial strains and biomarkers for personalized therapies. Growing regulatory acceptance of microbiome-based products and increasing collaborations between research institutions and industry players are accelerating innovation, making microbiome therapeutics a key focus area in modern healthcare.

Rising Prevalence of Chronic Diseases and Growing Focus on Personalized Medicine:

The increasing prevalence of chronic gastrointestinal disorders, obesity, diabetes, autoimmune diseases, and cancer is a major driver of the Human Microbiome Market. Scientific evidence linking the gut microbiome to immune function, metabolism, and overall health has encouraged pharmaceutical companies and healthcare providers to invest in microbiome research and personalized treatment strategies. Rising funding for microbiome-based drug development, expanding clinical trials, and advancements in next-generation sequencing technologies are further supporting market growth. Additionally, growing consumer awareness of gut health and increasing demand for targeted microbiome-based diagnostics and therapeutics continue to create significant opportunities for the market.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Functionality
  • 2.8 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Probiotics
    • 4.1.2 Prebiotics
    • 4.1.3 Synbiotics
    • 4.1.4 Postbiotics
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Foods
    • 4.2.2 Supplements
    • 4.2.3 Medical Foods
    • 4.2.4 Infant Formula
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Microbiome Sequencing
    • 4.3.2 Data Analysis
    • 4.3.3 Consulting
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Therapeutics
    • 4.5.2 Diagnostics
    • 4.5.3 Personalized Medicine
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Pharmaceutical Companies
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Research Institutes
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Functionality (2020-2035)
    • 4.7.1 Gut Health
    • 4.7.2 Immune System Support
    • 4.7.3 Metabolic Health
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-Premise
    • 4.8.2 Cloud-Based
    • 4.8.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Functionality
      • 5.2.1.8 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Functionality
      • 5.2.2.8 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Functionality
      • 5.2.3.8 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Functionality
      • 5.3.1.8 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Functionality
      • 5.3.2.8 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Functionality
      • 5.3.3.8 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Functionality
      • 5.4.1.8 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Functionality
      • 5.4.2.8 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Functionality
      • 5.4.3.8 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Functionality
      • 5.4.4.8 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Functionality
      • 5.4.5.8 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Functionality
      • 5.4.6.8 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Functionality
      • 5.4.7.8 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Functionality
      • 5.5.1.8 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Functionality
      • 5.5.2.8 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Functionality
      • 5.5.3.8 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Functionality
      • 5.5.4.8 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Functionality
      • 5.5.5.8 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Functionality
      • 5.5.6.8 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Functionality
      • 5.6.1.8 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Functionality
      • 5.6.2.8 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Functionality
      • 5.6.3.8 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Functionality
      • 5.6.4.8 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Functionality
      • 5.6.5.8 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Seres Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Enterome Bioscience
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Second Genome
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Vedanta Biosciences
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 4D Pharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Rebiotix
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Finch Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Synlogic
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 BiomeSense
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Microbiotica
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Evelo Biosciences
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Axial Biotherapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Kaleido Biosciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 AOBiome
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Metabiomics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Osel
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 MaaT Pharma
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 BiomX
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Quorum Innovations
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Eligo Bioscience
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us